Lavin J P
Diabetes. 1985 Jun;34 Suppl 2:24-7. doi: 10.2337/diab.34.2.s24.
Two thousand seventy-seven women attending a university-based prenatal clinic were screened for gestational diabetes. The patients were divided into two groups. Group 1 consisted of 959 patients with historic or clinical factors traditionally employed to identify patients as being at high risk for the occurrence of gestational diabetes. Group 2 consisted of the remaining 1118 patients. The O'Sullivan 50-g 1-h test, with an upper limit of normal for serum glucose of 150 mg/dl, was employed as the initial screening procedure. Patients with an abnormal screening test underwent a 3-h oral glucose tolerance test (GTT) with a 100-g load. The values recommended by the First American Diabetes Association Workshop-Conference on Gestational Diabetes were employed for interpretation. Group 1 patients underwent screening at their initial visit and again at 28 wk gestation. Group 2 patients underwent an identical screening sequence between 28 and 32 wk gestation. Cost analysis was performed. The prevalences of positive screening tests were 7.2% and 6.1%, and the frequencies of abnormal GTTs were 1.5% and 1.4% among group 1 and group 2 patients, respectively. These rates were not statistically significantly different. Overall, 46.7% and 53.5% of the cases of gestational diabetes were identified among the patients with and without risk factors, respectively. The total cost of the screening program was +9869.00. The cost per patient screened and the cost per case of gestational diabetes identified were +4.75 and +328.96, respectively. These results reemphasize the inadequacy of screening only those patients with traditional risk factors for gestational diabetes and demonstrate the feasibility of implementing a program of universal glucose screening among a large obstetric population.(ABSTRACT TRUNCATED AT 250 WORDS)
对2077名在大学附属产前诊所就诊的女性进行了妊娠期糖尿病筛查。患者被分为两组。第1组由959名具有传统上用于识别妊娠期糖尿病高危患者的病史或临床因素的患者组成。第2组由其余1118名患者组成。采用奥沙利文50克1小时试验作为初始筛查程序,血清葡萄糖正常上限为150毫克/分升。筛查试验异常的患者接受100克负荷的3小时口服葡萄糖耐量试验(GTT)。采用美国糖尿病协会第一届妊娠期糖尿病研讨会推荐的值进行解读。第1组患者在初次就诊时和妊娠28周时再次进行筛查。第2组患者在妊娠28至32周之间进行相同的筛查程序。进行了成本分析。第1组和第2组患者中筛查试验阳性的患病率分别为7.2%和6.1%,GTT异常的频率分别为1.5%和1.4%。这些比率在统计学上没有显著差异。总体而言,分别在有和无危险因素的患者中发现了46.7%和53.5%的妊娠期糖尿病病例。筛查项目的总成本为9869.00美元。每位接受筛查患者的成本和每例确诊的妊娠期糖尿病病例的成本分别为4.75美元和328.96美元。这些结果再次强调了仅对那些具有妊娠期糖尿病传统危险因素的患者进行筛查的不足,并证明了在大量产科人群中实施普遍葡萄糖筛查计划的可行性。(摘要截选至250字)